%PDF-1.4
%
79 0 obj
<>
endobj
80 0 obj
<>stream
application/pdf
0064.qxd
2005-03-30T14:30:43Z
QuarkXPressª 4.1: LaserWriter 8 8.7
2019-05-01T15:45:17-07:00
2019-05-01T15:45:17-07:00
Acrobat Distiller 4.05 for Macintosh
uuid:00dc17aa-1dd2-11b2-0a00-c609273d2300
uuid:00dc17b0-1dd2-11b2-0a00-1e0000000000
endstream
endobj
78 0 obj
<>
endobj
49 0 obj
<>
endobj
15 0 obj
<>
endobj
50 0 obj
<>
endobj
46 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
51 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
54 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Type/Page>>
endobj
85 0 obj
<>stream
1 g
/GS0 gs
0 783 m
0 783 l
f
q
-1 784 592 -785 re
W n
q
0 783 576 -783 re
W n
0 0 0 1 K
0.2 i 0.5 w
/GS1 gs
36 734.59 m
553.5 734.59 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
0.9649 Tc -0.4333 Tw 9 0 0 9 207.8098 743.0244 Tm
[(FEA)79.7 (TURE AR)19.6 (TICLE)]TJ
ET
0 0 0 0 k
242.38 38.95 310.62 -18 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 401.6016 21.6936 Tm
(Volume 23, Number 2, 2005)Tj
5 0 0 5 491.2051 22.4436 Tm
(\245)Tj
8 0 0 8 494.1836 21.6936 Tm
[(CLINICAL DIABE)27.1 (TES)]TJ
ET
0 0 0 0 k
36 38.95 26.5 -18 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 36 22.8225 Tm
(76)Tj
ET
0 0 0 0 k
214.5 693.31 162 -428.88 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
5 0 0 5 227.5 689.7169 Tm
(173)Tj
-0.00011 Tc 8 0 0 8 235 686.7168 Tm
[(Costa B,)-250.1 (Pinol C:)-195.2 (Acarbose in amb)19.7 (ulatory)]TJ
-2.4375 -1 Td
(treatment of non-insulin-dependent diabetes mel-)Tj
0 -1 TD
[(litus associated to imminent sulfon)14.8 (ylurea f)9.7 (ailure:)]TJ
T*
(a randomized-multicentric trial in primary health-)Tj
-0.0002 Tc T*
(care. )Tj
/T1_4 1 Tf
-0.00011 Tc [-0.5 (Diabetes Res Clin Pr)14.8 (act)]TJ
/T1_3 1 Tf
0 Tc 12.0913 0 Td
[(38:33\32040,)-250 (1997)]TJ
5 0 0 5 227.5 643.7169 Tm
(174)Tj
-0.00011 Tc -0.05479 Tw 8 0 0 8 235 640.7168 Tm
[(Rosenstock )-54.9 (J,)-250.1 (Bro)24.8 (wn A,)-250.1 (Fischer )-54.8 (J,)-250.1 (Jain A,)]TJ
-0.0177 Tw -2.4375 -1 Td
[(Littlejohn T)74 (,)-250.1 (Nadeau )-17.7 (D,)-250.1 (Sussman )37.1 (A,)-232.3 (T)79.9 (aylor T)74 (,)]TJ
0 Tw T*
[(Krol )54.8 (A,)-250.1 (Magner J:)-250.1 (Ef)24.8 (f)19.9 (icac)14.8 (y and safety of acar-)]TJ
T*
(bose in metformin-treated patients with type 2)Tj
T*
(diabetes. )Tj
/T1_4 1 Tf
[-0.2 (Diabetes Car)36.8 (e)]TJ
/T1_3 1 Tf
0 Tc 9.7932 0 Td
[(21:2050\3202055,)-250 (1998)]TJ
5 0 0 5 227.5 597.7169 Tm
(175)Tj
-0.00011 Tc 8 0 0 8 235 594.7168 Tm
[(Scorpiglione N,)-250.1 (Belf)19.7 (iglio M,)-250.1 (Carinci F)79.7 (,)]TJ
-2.4375 -1 Td
[(Ca)19.7 (v)24.8 (aliere D,)-250.1 (De Curtis )54.8 (A,)-250.1 (Franciosi M,)-250.1 (Mari E,)]TJ
0.00011 Tw T*
[(Sacco M,)-232.3 (T)79.9 (ognoni G,)-250.1 (Nicolucci )54.9 (A:)-232.3 (The ef)24.8 (fecti)24.8 (v)14.8 (e)0.1 (-)]TJ
0 Tw T*
[(ness,)-250.1 (safety and epidemiology of the use of acar-)]TJ
T*
(bose in the treatment of patients with type II dia-)Tj
T*
[(betes mellitus:)-250.1 (a model of medicine-based)]TJ
T*
[(e)25 (videcce. )]TJ
/T1_4 1 Tf
[-0.3 (Eur J Clin Pharmacol)]TJ
/T1_3 1 Tf
0 Tc 13.0818 0 Td
(43:179\320185,)Tj
-13.0818 -1 Td
(1999)Tj
5 0 0 5 227.5 527.7169 Tm
(176)Tj
-0.00011 Tc 8 0 0 8 235 524.7168 Tm
[(Holman RR,)-250.1 (Cull CA,)-232.3 (T)45 (u)0.1 (rner RC:)-195.2 (A ran-)]TJ
0.00011 Tw -2.4375 -1 Td
(domized double-blind trial of acarbose in type 2)Tj
T*
[(diabetes sho)24.8 (ws impro)14.8 (v)14.8 (ed glycemic control o)14.8 (v)14.8 (er 3)]TJ
0 Tw T*
(years \(UKPDS 44\). )Tj
/T1_4 1 Tf
[-0.4 (Diabetes Car)36.8 (e)]TJ
/T1_3 1 Tf
0 Tc 14.0696 0 Td
(22:960\320964,)Tj
-14.0696 -1 Td
(1999)Tj
5 0 0 5 227.5 481.7169 Tm
(177)Tj
-0.00011 Tc 8 0 0 8 235 478.7168 Tm
[(W)39.8 (illms B,)-250.1 (Ruge D:)-250.1 (Comparison of acar-)]TJ
-2.4375 -1 Td
(bose and metformin in patients with type 2 dia-)Tj
T*
[(betes mellitus insuf)24.8 (f)19.9 (iciently controlled with diet)]TJ
T*
[(and sulphon)14.8 (ylureas:)-250.1 (a randomized,)-250.1 (placebo-con-)]TJ
T*
[(trolled study)64.8 (.)-0.1 ( )]TJ
/T1_4 1 Tf
[-0.2 (Diabet Med)]TJ
/T1_3 1 Tf
0 Tc 10.4599 0 Td
[(16:755\320761,)-250 (1999)]TJ
5 0 0 5 227.5 435.7169 Tm
(178)Tj
-0.00011 Tc 0.00011 Tw 8 0 0 8 235 432.7168 Tm
[(Standl E,)-250.1 (Schernthaner G,)-250.1 (Rybka J,)-250.1 (Hane-)]TJ
0 Tw -2.4375 -1 Td
[(feld M,)-250.1 (Raptis SA,)-250.1 (Naditch L:)-250.1 (Impro)14.8 (v)14.8 (ed gly-)]TJ
T*
(caemic control with miglitol in inadequately-con-)Tj
T*
(trolled type 2 diabetics. )Tj
/T1_4 1 Tf
[-0.5 (Diabetes Res Clin Pr)14.8 (act)]TJ
/T1_3 1 Tf
0 Tc T*
[(51:205\320213,)-250 (2001)]TJ
5 0 0 5 227.5 389.7169 Tm
(179)Tj
-0.00011 Tc 0.00011 Tw 8 0 0 8 235 386.7168 Tm
[(Johnston PS,)-250.1 (Conif)24.8 (f RF)79.7 (,)-250.1 (Hoogwerf BJ,)]TJ
-2.4375 -1 Td
[(Santiago JV)128.8 (,)-250.1 (Pi-Sun)14.8 (yer FX,)-250.1 (Krol )54.9 (A:)-250.1 (Ef)24.8 (fects of the)]TJ
-0.0002 Tc T*
[(carbohydrase inhibitor miglitol in sulfon)14.7 (ylurea-)]TJ
-0.00011 Tc 0 Tw T*
(treated NIDDM patients. )Tj
/T1_4 1 Tf
[-0.1 (Diabetes Car)36.8 (e)]TJ
/T1_3 1 Tf
0 Tc T*
[(17:20\32029,)-250 (1994)]TJ
5 0 0 5 227.5 343.7169 Tm
(180)Tj
-0.0002 Tc 0.0002 Tw 8 0 0 8 235 340.7168 Tm
[(Einhorn D,)-250.2 (Rendell M,)-250.2 (Rosenzweig J,)-250.2 (Egan)]TJ
-0.00011 Tc -0.05479 Tw -2.4375 -1 Td
[(JW)91.7 (,)-250.1 (M)0.1 (athisen AL,)-250.1 (Schneider )-54.8 (RL:)-250.1 (Pioglitazone)]TJ
-0.0002 Tc 0.00011 Tw T*
(hydrochloride in combination with metformin in)Tj
-0.00011 Tc 0 Tw T*
[(the treatment of type 2 diabetes mellitus:)-250.1 (a ran-)]TJ
T*
[(domized,)-250.1 (placebo-controlled study)64.8 (.)-0.1 ( )]TJ
/T1_4 1 Tf
-0.0177 Tw [-0.5 (Clin Ther)]TJ
/T1_3 1 Tf
0 Tc 0 Tw T*
[(22:1395\3201409,)-250 (2000)]TJ
5 0 0 5 227.5 289.7169 Tm
(181)Tj
-0.00011 Tc 0.00011 Tw 8 0 0 8 235 286.7168 Tm
[(F)14.9 (onseca )49.8 (V)128.9 (,)-250.1 (Rosenstock J,)-250.1 (P)14.9 (atw)9.7 (ardhan R,)]TJ
0 Tw -2.4375 -1 Td
[(Salzman )54.8 (A:)-250.1 (Ef)24.8 (fect of metformin and rosiglitazone)]TJ
0.00011 Tw T*
[(combination therap)9.7 (y in patients with type 2 dia-)]TJ
ET
0 0 0 0 k
36 693.31 162 -427.81 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
0 Tc 0 Tw 5 0 0 5 49 689.7163 Tm
(164)Tj
-0.00031 Tc 0.0002 Tw 8 0 0 8 56.5 686.7162 Tm
[(Se)14.6 (gal P)110.5 (,)-250.3 (Feig PU,)-250.3 (S)-0.1 (chernthaner G,)-250.3 (Ratz-)]TJ
-0.00011 Tc 0.00011 Tw -2.4375 -1 Td
[(mann KP)110.7 (,)-250.1 (Rypka J,)-250.1 (Petzinna D,)-250.1 (Berlin C:)-232.3 (The)]TJ
0 Tw T*
[(ef)24.8 (f)19.9 (icac)14.8 (y and safety of miglitol therap)9.7 (y compared)]TJ
T*
(with glibenclamide in patients with NIDDM)Tj
T*
(inadequately controlled by diet alone. )Tj
/T1_4 1 Tf
15.3279 0 Td
(Diabetes)Tj
0 Tc -15.3279 -1 Td
[(Car)36.9 (e)]TJ
/T1_3 1 Tf
2.2129 0 Td
[(20:687\320691,)-250 (1997)]TJ
5 0 0 5 49 635.7163 Tm
(165)Tj
-0.00011 Tc 0.00011 Tw 8 0 0 8 56.5 632.7162 Tm
[(Kirk JK,)-250.1 (Pearce KA,)-250.1 (Michielutte R,)-250.1 (Sum-)]TJ
0 Tw -2.4375 -1 Td
[(merson JH:)-232.3 (T)35 (r)0.1 (oglitazone or metformin in combi-)]TJ
T*
[(nation with sulfon)14.8 (ylureas for patients with type 2)]TJ
T*
(diabetes? )Tj
/T1_4 1 Tf
-0.0002 Tc 0.00011 Tw [-0.1 (J F)74.8 (am Pr)14.7 (act)]TJ
/T1_3 1 Tf
0 Tc 0 Tw 9.1282 0 Td
[(48:879\320882,)-250 (1999)]TJ
5 0 0 5 49 596.7163 Tm
(166)Tj
-0.00011 Tc 8 0 0 8 56.5 593.7162 Tm
[(Horton ES,)-220.3 (W)0.1 (hitehouse F)79.7 (,)-250.1 (Ghazzi MN,)]TJ
-2.4375 -1.125 Td
[(V)110.8 (enable )17.7 (TC,)-220.3 (Whitcomb R)54.8 (W)36.9 (:)-232.1 (T)35 (roglitazone in)]TJ
0 -1.125 TD
[(combination with sulfon)14.8 (ylureas restores glycemic)]TJ
T*
(control in patients with type 2 diabetes. )Tj
/T1_4 1 Tf
15.9956 0 Td
(Diabetes)Tj
0 Tc -15.9956 -1.125 Td
[(Car)36.9 (e)]TJ
/T1_3 1 Tf
2.2129 0 Td
[(21:1462\3201469,)-250 (1998)]TJ
5 0 0 5 49 545.7163 Tm
(167)Tj
-0.00011 Tc -0.0177 Tw 8 0 0 8 56.5 542.7162 Tm
[(Marb)19.7 (ury T)74 (,)-250.1 (Huang )12 (WC,)-250.1 (Strange )-17.7 (P)110.7 (,)]TJ
0 Tw -2.4375 -1.125 Td
[(Lebo)24.8 (witz H:)-250.1 (Repaglinide v)14.8 (e)0.3 (rsus glyb)19.7 (uride:)-250.1 (a one-)]TJ
T*
(year comparison trial. )Tj
/T1_4 1 Tf
[-0.1 (Diabetes Res Clin Pr)14.8 (act)]TJ
/T1_3 1 Tf
0 Tc T*
[(43:155\320166,)-250 (1999)]TJ
5 0 0 5 49 504.2163 Tm
(168)Tj
-0.00011 Tc 8 0 0 8 56.5 501.2162 Tm
[(Landgraf R,)-250.1 (Bilo HJ,)-250.1 (Muller PG:)-195.2 (A com-)]TJ
-2.4375 -1.0625 Td
(parison of repaglinide and glibenclamide in the)Tj
0 -1.0625 TD
[(treatment of type 2 diabetic patients pre)25 (viously)]TJ
T*
[(treated with sulphon)14.8 (ylureas. )]TJ
/T1_4 1 Tf
[-0.5 (Eur J Clin Pharm)]TJ
/T1_3 1 Tf
0 Tc T*
[(55:165\320171,)-250 (1999)]TJ
5 0 0 5 49 455.7163 Tm
(169)Tj
-0.00011 Tc 8 0 0 8 56.5 452.7162 Tm
[(W)79.9 (olf)24.8 (fenb)19.7 (uttel BH,)-250.1 (Landgraf R:)-195.2 (A 1-year)]TJ
0.00011 Tw -2.4375 -1.0625 Td
(multicenter randomized double-blind comparison)Tj
0 Tw T*
[(of repaglinide and glyb)19.7 (uride for the treatment of)]TJ
T*
(type 2 diabetes. )Tj
/T1_4 1 Tf
6.4978 0 Td
[(Diabetes Car)36.8 (e )]TJ
/T1_3 1 Tf
0 Tc [-0.4 (22:463\320477,)-250 (1999)]TJ
5 0 0 5 49 416.2163 Tm
(170)Tj
8 0 0 8 56.5 413.2162 Tm
[(Moses R,)-250 (Slobodniuk R,)-250 (Bo)9.8 (yages S,)-250 (Colag-)]TJ
-0.00011 Tc -2.4375 -1 Td
[(iuri S,)-250.1 (Kidson )29.7 (W)91.8 (,)-250.1 (Carter J,)-250.1 (Donnelly )17.7 (T)74 (,)-250.1 (Mof)24.8 (f)19.9 (itt P)110.7 (,)]TJ
0 -1 TD
[(Hopkins H:)-250.1 (Ef)24.8 (fect of repaglinide addition to met-)]TJ
0.00011 Tw T*
[(formin monotherap)9.7 (y on glycemic control in)]TJ
0 Tw T*
(patients with type 2 diabetes. )Tj
/T1_4 1 Tf
11.8855 0 Td
[(Diabetes Car)36.8 (e)]TJ
/T1_3 1 Tf
0 Tc -11.8855 -1 Td
[(22:119\320124,)-250 (1999)]TJ
5 0 0 5 49 362.2163 Tm
(171)Tj
-0.00011 Tc 8 0 0 8 56.5 359.2162 Tm
[(Raskin P)110.8 (,)-250.1 (Jo)14.8 (v)24.8 (ano)14.8 (vic L,)-250.1 (Ber)17.7 (ger S,)-250.1 (Schw)9.7 (artz)]TJ
-0.0497 Tw -2.4375 -1 Td
[(S,)-220.3 (W)79.9 (oo V)128.9 (,)-250.1 (Ratner )-49.7 (R:)-250.1 (Repaglinide/troglitazone)]TJ
0 Tw T*
[(combination therap)9.7 (y:)-250.1 (impro)14.8 (v)14.8 (ed glycemic control)]TJ
T*
(in type 2 diabetes. )Tj
/T1_4 1 Tf
7.5256 0 Td
[(Diabetes Car)36.8 (e)]TJ
/T1_3 1 Tf
0 Tc 6.0171 0 Td
(23:979\320983,)Tj
-13.5427 -1 Td
(2000 )Tj
5 0 0 5 49 315.7163 Tm
(172)Tj
-0.00011 Tc 0.00011 Tw 8 0 0 8 56.5 312.7162 Tm
[(Erle G,)-250.1 (Lo)14.8 (vise S,)-250.1 (Stocchiero C,)-250.1 (Lora L,)]TJ
0 Tw -2.4375 -1.0625 Td
[(Coppini )54.8 (A,)-250.1 (Marchetti P)110.7 (,)-250.1 (Merante D:)-195.2 (A compari-)]TJ
0 -1.0625 TD
[(son of preconstituted,)-250.1 (f)19.9 (ix)14.8 (ed combinations of lo)24.8 (w-)]TJ
T*
[(dose glyb)19.7 (uride plus metformin v)14.8 (e)0.3 (rsus high-dose)]TJ
T*
[(glyb)19.7 (uride alone in the treatment of type 2 diabetic)]TJ
T*
(patients. )Tj
/T1_4 1 Tf
[-0.2 (Acta Diabetol)]TJ
/T1_3 1 Tf
0 Tc 9.4419 0 Td
[(36:61\32065,)-250 (1999)]TJ
ET
0 0 0 0 k
393 693.31 162 -502.31 re
f*
BT
0 0 0 1 k
/T1_3 1 Tf
-0.00011 Tc 8 0 0 8 394 686.7162 Tm
[(betes mellitus:)-250.1 (a randomized controlled trial.)]TJ
/T1_4 1 Tf
-0.00031 Tc 0 -1 TD
[(J)39.7 (AMA)]TJ
/T1_3 1 Tf
0 Tc 2.7085 0 Td
[(283:1695\3201702,)-250 (2000)]TJ
5 0 0 5 406 667.7163 Tm
(182)Tj
-0.00011 Tc 8 0 0 8 413.5 664.7162 Tm
[(W)79.9 (olf)24.8 (fenb)19.7 (uttel BH,)-250.1 (Gomis R,)-250.1 (Squatrito S,)]TJ
-2.4375 -1 Td
[(Jones NP)110.7 (,)-250.1 (P)14.9 (atw)9.7 (a)0.3 (rdhan RN:)-195.2 (Addition of lo)24.8 (w-dose)]TJ
0.00011 Tw T*
[(rosiglitazone to sulphon)14.8 (ylurea therap)9.7 (y impro)14.8 (v)14.8 (e)0.1 (s)]TJ
0 Tw T*
(glycaemic control in type 2 diabetic patients.)Tj
/T1_4 1 Tf
T*
(Diabet Med)Tj
/T1_3 1 Tf
0 Tc 4.9981 0 Td
[(17:40\32047,)-250 (2000)]TJ
5 0 0 5 406 620.7163 Tm
(183)Tj
-0.00011 Tc 8 0 0 8 413.5 617.7162 Tm
[(Buysschaert M,)-250.1 (Bobbioni E,)-250.1 (Starkie M,)]TJ
-2.4375 -1.125 Td
[(Frith L:)-232.3 (T)35 (r)0.1 (oglitazone in combination with sulpho-)]TJ
0 -1.125 TD
[(n)14.8 (ylurea impro)14.8 (v)14.8 (es glycaemic control in type 2 dia-)]TJ
0.00011 Tw T*
(betic patients inadequately controlled by sulpho-)Tj
0 Tw T*
[(n)14.8 (ylurea therap)9.7 (y alone. )]TJ
/T1_4 1 Tf
[-0.5 (Diabet Med)]TJ
/T1_3 1 Tf
0 Tc 14.1356 0 Td
(16:147\320153,)Tj
-14.1355 -1.125 Td
(1999)Tj
5 0 0 5 406 561.7163 Tm
(184)Tj
-0.00011 Tc -0.0898 Tw 8 0 0 8 413.5 558.7162 Tm
[(Iw)9.7 (amoto Y)128.9 (,)-250.1 (K)34.9 (osaka )-89.8 (K,)-250.1 (K)14.9 (uzuya )-72.1 (T)74 (,)-195.2 (Akanuma)]TJ
0 Tw -2.4375 -1 Td
[(Y)128.9 (,)-250.1 (Shigeta )89.8 (Y)128.9 (,)-250.1 (Kanek)9.7 (o )17.7 (T)49.9 (:)-249.9 (Ef)24.8 (fect of combination)]TJ
0.00011 Tw 0 -1 TD
[(therap)9.7 (y of troglitazone and sulphon)14.8 (ylureas in)]TJ
T*
(patients with type 2 diabetes who were poorly)Tj
T*
[(controlled by sulphon)14.8 (ylurea therap)9.7 (y alone. )]TJ
/T1_4 1 Tf
0 Tw 17.3581 0 Td
(Dia-)Tj
-17.3581 -1 Td
(bet Med)Tj
/T1_3 1 Tf
0 Tc 3.4983 0 Td
[(13:365\320370,)-250 (1996)]TJ
ET
0.25 w
394 500.84 m
554 500.84 l
S
BT
/T1_4 1 Tf
-0.0126 Tc 10 0 0 10 394 488.7162 Tm
[(Bonnie Kimmel,)-237.6 (MD,)-237.6 (is a senior r)36.8 (esident)]TJ
0.00011 Tw 0 -1.2 TD
[(in g)9.7 (ener)14.8 (al internal medicine at the )75 (Y)91.8 (a)0.1 (le)]TJ
T*
[(Primary Car)36.8 (e Residency Pr)44.8 (o)9.7 (g)-0.1 (r)14.9 (am in)]TJ
T*
[(W)91.9 (a)-0.1 (terb)19.7 (ury and Ne)14.8 (w Haven,)-237.6 (Conn. Silvio)]TJ
T*
[(E. Inzucc)14.8 (hi,)-237.6 (MD,)-237.6 (i)-0.1 (s a pr)44.8 (ofessor of medi-)]TJ
0 Tw T*
[(cine and clinical dir)36.8 (ector of the Section)]TJ
T*
[(of Endocrinolo)9.7 (gy at )74.9 (Y)91.8 (ale Univer)9.7 (sity)]TJ
T*
[(Sc)14.8 (hool of Medicine and dir)36.7 (ector of the)]TJ
0.00011 Tw T*
[(Y)91.8 (ale Diabetes Center at )75 (Y)91.8 (ale-Ne)14.8 (w)-0.1 ( Haven)]TJ
T*
[(Hospital in Ne)14.8 (w Haven,)-237.6 (Conn. )]TJ
/T1_5 1 Tf
0 Tw 0 -2.5 TD
(Note of disclosure:)Tj
/T1_4 1 Tf
0.00011 Tw 7.7752 0 Td
[(Dr)110.8 (. Inzucc)14.8 (hi has)]TJ
0 Tw -7.7752 -1.2 Td
[(served on advisory boar)36.9 (ds for )17.8 (T)91.9 (a)0.1 (k)9.8 (eda,)]TJ
0.00011 Tw 0 -1.2 TD
[(Pf)19.7 (izer)110.8 (,)-237.6 (and No)9.7 (vartis. He has r)36.7 (eceived)]TJ
T*
[(honor)14.8 (aria for speaking enga)9.7 (g)9.7 (ements)]TJ
-0.0177 Tw T*
[(fr)44.8 (om T)91.8 (ak)9.7 (eda,)-237.6 (GlaxoSmithKline)9.7 (,)-237.6 (and)]TJ
0.00011 Tw T*
[(Bristol-Myer)9.7 (s Squibb)39.7 (. )17.8 (These companies)]TJ
T*
[(mark)9.8 (et or)14.8 (al pharmaceutical pr)44.8 (oducts for)]TJ
0 Tw T*
[(the tr)36.8 (eatment of diabetes. )]TJ
ET
Q
Q
endstream
endobj
11 0 obj
<>
endobj
10 0 obj
<>
endobj
9 0 obj
<>
endobj
6 0 obj
<>
endobj
27 0 obj
<>
endobj
23 0 obj
<>
endobj
71 0 obj
<>
endobj
72 0 obj
<>stream
HlS}PػK88Cq〃=}N|#_aAQLJ&"fj%ӉMty줋3i7{z`>D"Ys f}:>-!5ڢ1˱0 @KUJQ"ǿNNsT֏d3.(ZBBn 0>=j7[öoۼ?ðeawRt!;oelQk&Ncѥnar}W8ldVϳiRu.5o&ݬcwGcjcbSN.|gC&FaX0b1`J>LX46"r|3#%'_>U{ A gPj%,6HHaugVb>[ڪF9TYCi{R>
^ELqebnέ"4^f1#W0H/T%#V
Z,T2XA)N}Pu2&{sk==~QKEZU8w9
+a'V;ʴo[ʺKA'F2>|*Q;]|>-w;\`oOBl¸qU儡GL95YA깻8T~1
lV^Y
;WqƓmr>-
@5\#7js6̭ X[J#M0
fDV
G^LR*Ҽ㤱zlO˅W> =̡ol;4(>@ GZLk*˰b/{҅
T9x(E\XMSk>0V(rouoUMN"/G&hb
Dk.
tǬ^n",xzm.XAU.x'&(Z4.,p&|qwc
8Ya
8?ÊLP,*9tU\^Ww2~O9_߾.p@NdY8sP{+dzrjj,)bWiuҝ6 u$:6v^阽1^5
Ejmٴ'x
V.HסcTV
O[-5#lRVUqd/QxG?|s"57~Mx>,>LSĉ}*78^!d@r雑IၠQeTgu%R#CczR&c;sD8am>mvGv}Lm}0;zߑ5:#OўJeF%ŠyѦagȢ4+2&I(y
y;00=D6U sOLͨyxi
[Df׀C4bU8t